Nofazinlimab

DB18852InvestigationalProtein Based Therapies

Nofazinlimab is under investigation in clinical trial NCT04194775 (A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Antibody cs1003 · Immunoglobulin g4 (223-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal cs1003 .gamma.4-chain), disulfide with human-mus musculus monoclonal cs1003 .kappa.-chain, dimer · Recombinant pd-1 mab cs1003
Code names: CS-1003

Resolves to

Compound

UNII42T48Q7A6OCAS2377845-98-0

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nofazinlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account